JP2007514746A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007514746A5 JP2007514746A5 JP2006545364A JP2006545364A JP2007514746A5 JP 2007514746 A5 JP2007514746 A5 JP 2007514746A5 JP 2006545364 A JP2006545364 A JP 2006545364A JP 2006545364 A JP2006545364 A JP 2006545364A JP 2007514746 A5 JP2007514746 A5 JP 2007514746A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- composition
- compound
- substituted
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 113
- 239000000203 mixture Substances 0.000 claims 98
- 150000003839 salts Chemical class 0.000 claims 43
- 125000000217 alkyl group Chemical group 0.000 claims 40
- 125000001424 substituent group Chemical group 0.000 claims 40
- 125000001072 heteroaryl group Chemical group 0.000 claims 25
- 229910052739 hydrogen Inorganic materials 0.000 claims 22
- 125000000753 cycloalkyl group Chemical group 0.000 claims 20
- 201000010099 disease Diseases 0.000 claims 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 18
- 208000002193 Pain Diseases 0.000 claims 17
- 208000033808 peripheral neuropathy Diseases 0.000 claims 17
- 125000003118 aryl group Chemical group 0.000 claims 16
- 201000001119 neuropathy Diseases 0.000 claims 16
- 230000007823 neuropathy Effects 0.000 claims 16
- 229910052736 halogen Inorganic materials 0.000 claims 15
- 150000002367 halogens Chemical group 0.000 claims 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims 14
- 208000011580 syndromic disease Diseases 0.000 claims 14
- 230000036407 pain Effects 0.000 claims 13
- 206010052779 Transplant rejections Diseases 0.000 claims 12
- 230000001363 autoimmune Effects 0.000 claims 12
- 230000001684 chronic effect Effects 0.000 claims 12
- 125000003710 aryl alkyl group Chemical group 0.000 claims 11
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 206010047115 Vasculitis Diseases 0.000 claims 9
- 230000005784 autoimmunity Effects 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- 230000001404 mediated effect Effects 0.000 claims 9
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 9
- 208000023275 Autoimmune disease Diseases 0.000 claims 8
- 102000019034 Chemokines Human genes 0.000 claims 8
- 108010012236 Chemokines Proteins 0.000 claims 8
- 206010065390 Inflammatory pain Diseases 0.000 claims 8
- 206010063837 Reperfusion injury Diseases 0.000 claims 8
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 8
- 208000014674 injury Diseases 0.000 claims 8
- 125000003107 substituted aryl group Chemical group 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 239000003112 inhibitor Substances 0.000 claims 7
- 206010006448 Bronchiolitis Diseases 0.000 claims 6
- 208000009525 Myocarditis Diseases 0.000 claims 6
- 206010040070 Septic Shock Diseases 0.000 claims 6
- 241000700605 Viruses Species 0.000 claims 6
- 206010003246 arthritis Diseases 0.000 claims 6
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 6
- -1 ipropyl Chemical group 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 201000006417 multiple sclerosis Diseases 0.000 claims 6
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 5
- 208000034656 Contusions Diseases 0.000 claims 5
- 206010011878 Deafness Diseases 0.000 claims 5
- 206010021143 Hypoxia Diseases 0.000 claims 5
- 239000005557 antagonist Substances 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- 208000030533 eye disease Diseases 0.000 claims 5
- 230000010370 hearing loss Effects 0.000 claims 5
- 231100000888 hearing loss Toxicity 0.000 claims 5
- 208000016354 hearing loss disease Diseases 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 201000008482 osteoarthritis Diseases 0.000 claims 5
- 208000002574 reactive arthritis Diseases 0.000 claims 5
- 208000023504 respiratory system disease Diseases 0.000 claims 5
- 238000002054 transplantation Methods 0.000 claims 5
- 208000009137 Behcet syndrome Diseases 0.000 claims 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims 4
- 208000011231 Crohn disease Diseases 0.000 claims 4
- 206010014561 Emphysema Diseases 0.000 claims 4
- 208000007465 Giant cell arteritis Diseases 0.000 claims 4
- 201000005569 Gout Diseases 0.000 claims 4
- 206010019233 Headaches Diseases 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 4
- 206010033645 Pancreatitis Diseases 0.000 claims 4
- 201000004681 Psoriasis Diseases 0.000 claims 4
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 4
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 4
- 208000006011 Stroke Diseases 0.000 claims 4
- 208000007536 Thrombosis Diseases 0.000 claims 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 4
- 230000001154 acute effect Effects 0.000 claims 4
- 208000005298 acute pain Diseases 0.000 claims 4
- 230000002491 angiogenic effect Effects 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 206010006451 bronchitis Diseases 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 4
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 4
- 231100000869 headache Toxicity 0.000 claims 4
- 208000006454 hepatitis Diseases 0.000 claims 4
- 231100000283 hepatitis Toxicity 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- 208000004296 neuralgia Diseases 0.000 claims 4
- 208000021722 neuropathic pain Diseases 0.000 claims 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 208000005987 polymyositis Diseases 0.000 claims 4
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 4
- 201000000306 sarcoidosis Diseases 0.000 claims 4
- 206010043207 temporal arteritis Diseases 0.000 claims 4
- 230000008733 trauma Effects 0.000 claims 4
- 206010047470 viral myocarditis Diseases 0.000 claims 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 3
- 206010003267 Arthritis reactive Diseases 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 201000006474 Brain Ischemia Diseases 0.000 claims 3
- 206010006458 Bronchitis chronic Diseases 0.000 claims 3
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 3
- 206010009137 Chronic sinusitis Diseases 0.000 claims 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 3
- 208000007882 Gastritis Diseases 0.000 claims 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims 3
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 3
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 3
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 3
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 3
- 206010024453 Ligament sprain Diseases 0.000 claims 3
- 208000027530 Meniere disease Diseases 0.000 claims 3
- 208000003251 Pruritus Diseases 0.000 claims 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 3
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 claims 3
- 206010039710 Scleroderma Diseases 0.000 claims 3
- 208000010040 Sprains and Strains Diseases 0.000 claims 3
- 208000007107 Stomach Ulcer Diseases 0.000 claims 3
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 3
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 3
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 3
- 206010046851 Uveitis Diseases 0.000 claims 3
- 208000027418 Wounds and injury Diseases 0.000 claims 3
- 230000002378 acidificating effect Effects 0.000 claims 3
- 208000038016 acute inflammation Diseases 0.000 claims 3
- 230000006022 acute inflammation Effects 0.000 claims 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 3
- 230000010085 airway hyperresponsiveness Effects 0.000 claims 3
- 208000007502 anemia Diseases 0.000 claims 3
- 230000033115 angiogenesis Effects 0.000 claims 3
- 239000000935 antidepressant agent Substances 0.000 claims 3
- 229940005513 antidepressants Drugs 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 201000008937 atopic dermatitis Diseases 0.000 claims 3
- 208000010353 central nervous system vasculitis Diseases 0.000 claims 3
- 206010008118 cerebral infarction Diseases 0.000 claims 3
- 239000000812 cholinergic antagonist Substances 0.000 claims 3
- 208000007451 chronic bronchitis Diseases 0.000 claims 3
- 208000037976 chronic inflammation Diseases 0.000 claims 3
- 230000006020 chronic inflammation Effects 0.000 claims 3
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims 3
- 230000009519 contusion Effects 0.000 claims 3
- 239000013078 crystal Substances 0.000 claims 3
- 230000006378 damage Effects 0.000 claims 3
- 125000000524 functional group Chemical group 0.000 claims 3
- 201000005917 gastric ulcer Diseases 0.000 claims 3
- 208000007565 gingivitis Diseases 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 230000007954 hypoxia Effects 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 230000003551 muscarinic effect Effects 0.000 claims 3
- 206010028417 myasthenia gravis Diseases 0.000 claims 3
- 208000031225 myocardial ischemia Diseases 0.000 claims 3
- 201000008383 nephritis Diseases 0.000 claims 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 3
- 230000000414 obstructive effect Effects 0.000 claims 3
- 230000010412 perfusion Effects 0.000 claims 3
- 230000002980 postoperative effect Effects 0.000 claims 3
- 230000000241 respiratory effect Effects 0.000 claims 3
- 208000037803 restenosis Diseases 0.000 claims 3
- 150000003431 steroids Chemical class 0.000 claims 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims 3
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims 2
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 claims 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims 2
- 206010059245 Angiopathy Diseases 0.000 claims 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 2
- 208000032467 Aplastic anaemia Diseases 0.000 claims 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 2
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 2
- 208000023328 Basedow disease Diseases 0.000 claims 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 2
- 208000019838 Blood disease Diseases 0.000 claims 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 2
- 208000000668 Chronic Pancreatitis Diseases 0.000 claims 2
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims 2
- 208000015943 Coeliac disease Diseases 0.000 claims 2
- 206010055665 Corneal neovascularisation Diseases 0.000 claims 2
- 206010011224 Cough Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 206010012442 Dermatitis contact Diseases 0.000 claims 2
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 2
- 208000000059 Dyspnea Diseases 0.000 claims 2
- 206010013975 Dyspnoeas Diseases 0.000 claims 2
- 206010015943 Eye inflammation Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 2
- 108010072051 Glatiramer Acetate Proteins 0.000 claims 2
- 208000005232 Glossitis Diseases 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 2
- 208000015023 Graves' disease Diseases 0.000 claims 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 2
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims 2
- 208000004454 Hyperalgesia Diseases 0.000 claims 2
- 206010020591 Hypercapnia Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 206010062767 Hypophysitis Diseases 0.000 claims 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- 229940124761 MMP inhibitor Drugs 0.000 claims 2
- 201000009906 Meningitis Diseases 0.000 claims 2
- 102000029749 Microtubule Human genes 0.000 claims 2
- 108091022875 Microtubule Proteins 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 208000034486 Multi-organ failure Diseases 0.000 claims 2
- 208000010718 Multiple Organ Failure Diseases 0.000 claims 2
- 208000000112 Myalgia Diseases 0.000 claims 2
- 201000002481 Myositis Diseases 0.000 claims 2
- 206010061876 Obstruction Diseases 0.000 claims 2
- 206010030216 Oesophagitis Diseases 0.000 claims 2
- 208000003435 Optic Neuritis Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 206010033165 Ovarian failure Diseases 0.000 claims 2
- 206010033647 Pancreatitis acute Diseases 0.000 claims 2
- 206010033649 Pancreatitis chronic Diseases 0.000 claims 2
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 2
- 206010034277 Pemphigoid Diseases 0.000 claims 2
- 241000721454 Pemphigus Species 0.000 claims 2
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 208000006399 Premature Obstetric Labor Diseases 0.000 claims 2
- 206010036600 Premature labour Diseases 0.000 claims 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 2
- 208000033464 Reiter syndrome Diseases 0.000 claims 2
- 208000037656 Respiratory Sounds Diseases 0.000 claims 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 208000000924 Right ventricular hypertrophy Diseases 0.000 claims 2
- 206010039705 Scleritis Diseases 0.000 claims 2
- 206010040744 Sinus headache Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 claims 2
- 108091008605 VEGF receptors Proteins 0.000 claims 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 2
- 206010047642 Vitiligo Diseases 0.000 claims 2
- 206010047924 Wheezing Diseases 0.000 claims 2
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims 2
- 206010000496 acne Diseases 0.000 claims 2
- 201000003229 acute pancreatitis Diseases 0.000 claims 2
- 208000002353 alcoholic hepatitis Diseases 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 208000002029 allergic contact dermatitis Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 208000004631 alopecia areata Diseases 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 230000001430 anti-depressive effect Effects 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 201000009267 bronchiectasis Diseases 0.000 claims 2
- 208000034526 bruise Diseases 0.000 claims 2
- 208000000594 bullous pemphigoid Diseases 0.000 claims 2
- 208000025997 central nervous system neoplasm Diseases 0.000 claims 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 2
- 230000007882 cirrhosis Effects 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 201000000159 corneal neovascularization Diseases 0.000 claims 2
- 229940111134 coxibs Drugs 0.000 claims 2
- 201000003278 cryoglobulinemia Diseases 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 claims 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000000292 ehrlichiosis Diseases 0.000 claims 2
- 206010014599 encephalitis Diseases 0.000 claims 2
- 201000011114 epidermolysis bullosa acquisita Diseases 0.000 claims 2
- 208000006881 esophagitis Diseases 0.000 claims 2
- 239000003172 expectorant agent Substances 0.000 claims 2
- 230000003176 fibrotic effect Effects 0.000 claims 2
- 229960003776 glatiramer acetate Drugs 0.000 claims 2
- 239000003862 glucocorticoid Substances 0.000 claims 2
- 210000003714 granulocyte Anatomy 0.000 claims 2
- 208000014951 hematologic disease Diseases 0.000 claims 2
- 230000002489 hematologic effect Effects 0.000 claims 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims 2
- 230000002949 hemolytic effect Effects 0.000 claims 2
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 2
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 230000009610 hypersensitivity Effects 0.000 claims 2
- 208000018875 hypoxemia Diseases 0.000 claims 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 201000006334 interstitial nephritis Diseases 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 201000011486 lichen planus Diseases 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 201000004792 malaria Diseases 0.000 claims 2
- 229910052751 metal Inorganic materials 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- 210000004688 microtubule Anatomy 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 2
- 206010033072 otitis externa Diseases 0.000 claims 2
- 201000004535 ovarian dysfunction Diseases 0.000 claims 2
- 231100000539 ovarian failure Toxicity 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 2
- 201000001245 periodontitis Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 2
- 208000026440 premature labor Diseases 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims 2
- 230000036303 septic shock Effects 0.000 claims 2
- 201000005671 spondyloarthropathy Diseases 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 229940037128 systemic glucocorticoids Drugs 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 206010043554 thrombocytopenia Diseases 0.000 claims 2
- 208000009174 transverse myelitis Diseases 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 241001529453 unidentified herpesvirus Species 0.000 claims 2
- 208000019553 vascular disease Diseases 0.000 claims 2
- GWNVDXQDILPJIG-CCHJCNDSSA-N 11-trans-Leukotriene C4 Chemical compound CCCCC\C=C/C\C=C\C=C\C=C\[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-CCHJCNDSSA-N 0.000 claims 1
- 239000003185 4 aminobutyric acid B receptor stimulating agent Substances 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010003011 Appendicitis Diseases 0.000 claims 1
- 208000036487 Arthropathies Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000027496 Behcet disease Diseases 0.000 claims 1
- 102100039705 Beta-2 adrenergic receptor Human genes 0.000 claims 1
- 208000010392 Bone Fractures Diseases 0.000 claims 1
- 206010006811 Bursitis Diseases 0.000 claims 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims 1
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 claims 1
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 claims 1
- 229940124638 COX inhibitor Drugs 0.000 claims 1
- 241000222122 Candida albicans Species 0.000 claims 1
- 206010007134 Candida infections Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000001387 Causalgia Diseases 0.000 claims 1
- 206010064012 Central pain syndrome Diseases 0.000 claims 1
- 208000018380 Chemical injury Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 229940122858 Elastase inhibitor Drugs 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 208000004232 Enteritis Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 206010017076 Fracture Diseases 0.000 claims 1
- 206010018634 Gouty Arthritis Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 108010051696 Growth Hormone Proteins 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 208000009889 Herpes Simplex Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims 1
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000035154 Hyperesthesia Diseases 0.000 claims 1
- 206010058490 Hyperoxia Diseases 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 102000003996 Interferon-beta Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 claims 1
- 206010022773 Intracranial pressure increased Diseases 0.000 claims 1
- 206010022998 Irritability Diseases 0.000 claims 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims 1
- 208000012659 Joint disease Diseases 0.000 claims 1
- 208000000913 Kidney Calculi Diseases 0.000 claims 1
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 claims 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010049565 Muscle fatigue Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 1
- 206010051606 Necrotising colitis Diseases 0.000 claims 1
- 206010029148 Nephrolithiasis Diseases 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 claims 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 claims 1
- 206010033078 Otitis media Diseases 0.000 claims 1
- 108010014865 PLIalpha Proteins 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 1
- 229940123898 Phospholipase A2 inhibitor Drugs 0.000 claims 1
- 229940117896 Phospholipase D inhibitor Drugs 0.000 claims 1
- 206010034960 Photophobia Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 206010037423 Pulmonary oedema Diseases 0.000 claims 1
- 206010037549 Purpura Diseases 0.000 claims 1
- 241001672981 Purpura Species 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 206010037779 Radiculopathy Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims 1
- 206010038687 Respiratory distress Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038910 Retinitis Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 208000008765 Sciatica Diseases 0.000 claims 1
- 229940124639 Selective inhibitor Drugs 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims 1
- 102100038803 Somatotropin Human genes 0.000 claims 1
- 206010041660 Splenomegaly Diseases 0.000 claims 1
- 208000006045 Spondylarthropathies Diseases 0.000 claims 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 1
- 208000000491 Tendinopathy Diseases 0.000 claims 1
- 206010043255 Tendonitis Diseases 0.000 claims 1
- 108010039185 Tenecteplase Proteins 0.000 claims 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 206010046914 Vaginal infection Diseases 0.000 claims 1
- 201000008100 Vaginitis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 229960000446 abciximab Drugs 0.000 claims 1
- 239000002597 adenosine A2 receptor agonist Substances 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 claims 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 206010053552 allodynia Diseases 0.000 claims 1
- 229960003318 alteplase Drugs 0.000 claims 1
- 229960000836 amitriptyline Drugs 0.000 claims 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000002921 anti-spasmodic effect Effects 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 239000003435 antirheumatic agent Substances 0.000 claims 1
- 229940124575 antispasmodic agent Drugs 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 201000004339 autoimmune neuropathy Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 201000005008 bacterial sepsis Diseases 0.000 claims 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 claims 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 1
- 230000008512 biological response Effects 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- 239000000168 bronchodilator agent Substances 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 159000000007 calcium salts Chemical class 0.000 claims 1
- 201000003984 candidiasis Diseases 0.000 claims 1
- 229960000623 carbamazepine Drugs 0.000 claims 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims 1
- 229910002092 carbon dioxide Inorganic materials 0.000 claims 1
- 239000001569 carbon dioxide Substances 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 229960000590 celecoxib Drugs 0.000 claims 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 claims 1
- 208000018631 connective tissue disease Diseases 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 239000000850 decongestant Substances 0.000 claims 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 claims 1
- 229960003638 dopamine Drugs 0.000 claims 1
- 208000000718 duodenal ulcer Diseases 0.000 claims 1
- 210000001198 duodenum Anatomy 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 239000003602 elastase inhibitor Substances 0.000 claims 1
- 208000011099 endometrial disease Diseases 0.000 claims 1
- 230000003419 expectorant effect Effects 0.000 claims 1
- 238000000605 extraction Methods 0.000 claims 1
- 239000003527 fibrinolytic agent Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 229960002870 gabapentin Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 239000000122 growth hormone Substances 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 239000000938 histamine H1 antagonist Substances 0.000 claims 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 claims 1
- 230000000222 hyperoxic effect Effects 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 229960000905 indomethacin Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims 1
- 229960000991 ketoprofen Drugs 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 208000037805 labour Diseases 0.000 claims 1
- 210000001821 langerhans cell Anatomy 0.000 claims 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 claims 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 1
- 238000009593 lumbar puncture Methods 0.000 claims 1
- 210000004705 lumbosacral region Anatomy 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
- 229960001156 mitoxantrone Drugs 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 229940066491 mucolytics Drugs 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- 229960002009 naproxen Drugs 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- 201000009240 nasopharyngitis Diseases 0.000 claims 1
- 230000001338 necrotic effect Effects 0.000 claims 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 239000002742 neurokinin 1 receptor antagonist Substances 0.000 claims 1
- 239000002746 neurokinin 2 receptor antagonist Substances 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 239000002762 nociceptin receptor agonist Substances 0.000 claims 1
- 229960001158 nortriptyline Drugs 0.000 claims 1
- 208000030212 nutrition disease Diseases 0.000 claims 1
- 208000019180 nutritional disease Diseases 0.000 claims 1
- 201000005737 orchitis Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims 1
- 206010034674 peritonitis Diseases 0.000 claims 1
- 239000003358 phospholipase A2 inhibitor Substances 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 229960002702 piroxicam Drugs 0.000 claims 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 1
- 229920001296 polysiloxane Polymers 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims 1
- 229960001233 pregabalin Drugs 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 208000005333 pulmonary edema Diseases 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 238000010992 reflux Methods 0.000 claims 1
- 230000004043 responsiveness Effects 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 229960000371 rofecoxib Drugs 0.000 claims 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical group C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims 1
- 230000001953 sensory effect Effects 0.000 claims 1
- 208000013223 septicemia Diseases 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 229910052710 silicon Inorganic materials 0.000 claims 1
- 239000010703 silicon Substances 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims 1
- 229960001940 sulfasalazine Drugs 0.000 claims 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229960004964 temozolomide Drugs 0.000 claims 1
- 201000004415 tendinitis Diseases 0.000 claims 1
- 229960000216 tenecteplase Drugs 0.000 claims 1
- 208000012720 thalamic disease Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229960000103 thrombolytic agent Drugs 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 230000008736 traumatic injury Effects 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 208000014001 urinary system disease Diseases 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
- 0 CC(*)(*)Cc1c(cccn2)c2ccc1 Chemical compound CC(*)(*)Cc1c(cccn2)c2ccc1 0.000 description 13
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53131103P | 2003-12-19 | 2003-12-19 | |
| US60/531,311 | 2003-12-19 | ||
| US53171303P | 2003-12-22 | 2003-12-22 | |
| US60/531,713 | 2003-12-22 | ||
| PCT/US2004/042060 WO2005066147A1 (en) | 2003-12-19 | 2004-12-16 | Thiadiazoles as cxc- and cc- chemokine receptor ligands |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011030301A Division JP2011093943A (ja) | 2003-12-19 | 2011-02-15 | Ｃｘｃ−ケモカインレセプターリガンドおよびｃｃ−ケモカインレセプターリガンドとしてのチアジアゾール |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007514746A JP2007514746A (ja) | 2007-06-07 |
| JP2007514746A5 true JP2007514746A5 (cg-RX-API-DMAC7.html) | 2008-02-07 |
| JP4939229B2 JP4939229B2 (ja) | 2012-05-23 |
Family
ID=34752970
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006545364A Expired - Fee Related JP4939229B2 (ja) | 2003-12-19 | 2004-12-16 | Ｃｘｃ−ケモカインレセプターリガンドおよびｃｃ−ケモカインレセプターリガンドとしてのチアジアゾール |
| JP2011030301A Withdrawn JP2011093943A (ja) | 2003-12-19 | 2011-02-15 | Ｃｘｃ−ケモカインレセプターリガンドおよびｃｃ−ケモカインレセプターリガンドとしてのチアジアゾール |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011030301A Withdrawn JP2011093943A (ja) | 2003-12-19 | 2011-02-15 | Ｃｘｃ−ケモカインレセプターリガンドおよびｃｃ−ケモカインレセプターリガンドとしてのチアジアゾール |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7338968B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1694659B8 (cg-RX-API-DMAC7.html) |
| JP (2) | JP4939229B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN1918138B (cg-RX-API-DMAC7.html) |
| AR (1) | AR046791A1 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE406356T1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2550189A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE602004016211D1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2308299T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA06007076A (cg-RX-API-DMAC7.html) |
| MY (1) | MY139808A (cg-RX-API-DMAC7.html) |
| TW (1) | TW200528450A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005066147A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60326080D1 (en) * | 2002-10-09 | 2009-03-19 | Schering Corp | Thiadiazoldioxide und thiadiazoloxide als cxc- und cc-chemokinrezeptor liganden |
| TW200530231A (en) * | 2003-12-22 | 2005-09-16 | Schering Corp | Isothiazole dioxides as CXC-and CC-chemokine receptor ligands |
| US7326729B2 (en) * | 2004-05-12 | 2008-02-05 | Schering Corporation | CXCR1 and CXCR2 chemokine antagonists |
| CA2613607A1 (en) * | 2005-06-29 | 2007-01-04 | Schering Corporation | Di-substituted oxadiazoles as cxc-chemokine receptor ligands |
| ES2353401T3 (es) * | 2005-06-29 | 2011-03-01 | Schering Corporation | Oxidiazolopirazinas y tiadiazolopirazinas 5,6-di-sustituidas como ligandos del receptor de cxc-quimiocina. |
| SI2455382T1 (sl) | 2005-12-13 | 2017-03-31 | Incyte Holdings Corporation | S heteroarilom substituirani pirolo(2,3b)piridini in pirolo(2,3-b)pirimidini kot zaviralci janus kinaze |
| ES2467665T5 (es) | 2007-06-13 | 2022-11-03 | Incyte Holdings Corp | Sales del inhibidor de cinasas Janus (R)-3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopentilpropanonitrilo |
| WO2009019167A1 (en) | 2007-08-08 | 2009-02-12 | Merck Serono S.A. | 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (s1p) receptor for the treatment of multiple sclerosis |
| EP2116618A1 (en) | 2008-05-09 | 2009-11-11 | Agency for Science, Technology And Research | Diagnosis and treatment of Kawasaki disease |
| CL2009001884A1 (es) * | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| WO2010050445A1 (ja) * | 2008-10-27 | 2010-05-06 | 武田薬品工業株式会社 | 二環性化合物 |
| MY156727A (en) | 2009-05-22 | 2016-03-15 | Incyte Corp | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| PT2432472T (pt) | 2009-05-22 | 2019-12-09 | Incyte Holdings Corp | 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octano- ou heptano-nitrilo como inibidores de jak |
| WO2011028685A1 (en) | 2009-09-01 | 2011-03-10 | Incyte Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| CA2783699C (en) | 2009-12-08 | 2019-01-15 | Case Western Reserve University | Primary amine compounds for treating ocular disorders |
| US20130085133A1 (en) * | 2010-02-08 | 2013-04-04 | Sourthern Research Institute Office of Commercialization and Intellectual Prop. | Anti-viral treatment and assay to screenfor anti-viral agent |
| MX354212B (es) | 2010-03-10 | 2018-02-19 | Incyte Corp | Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1). |
| US20110288107A1 (en) | 2010-05-21 | 2011-11-24 | Bhavnish Parikh | Topical formulation for a jak inhibitor |
| CA2818542A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| EP2640725B1 (en) | 2010-11-19 | 2015-01-07 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
| WO2012177606A1 (en) | 2011-06-20 | 2012-12-27 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| WO2013173720A1 (en) | 2012-05-18 | 2013-11-21 | Incyte Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| US8865723B2 (en) | 2012-10-25 | 2014-10-21 | Tetra Discovery Partners Llc | Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury |
| ES2880814T3 (es) | 2012-11-15 | 2021-11-25 | Incyte Holdings Corp | Formas de dosificación de liberación sostenida de ruxolitinib |
| EP3489239B1 (en) | 2013-03-06 | 2021-09-15 | Incyte Holdings Corporation | Processes and intermediates for making a jak inhibitor |
| TWI789516B (zh) | 2013-08-07 | 2023-01-11 | 美商英塞特公司 | Jak1抑制劑之持續釋放劑型 |
| US9763992B2 (en) | 2014-02-13 | 2017-09-19 | Father Flanagan's Boys' Home | Treatment of noise induced hearing loss |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
| HRP20220510T1 (hr) | 2018-01-30 | 2022-05-27 | Incyte Corporation | Postupci za pripravu (1-(3-fluoro-2-(trifluorometil)izonikotinil) piperidin-4-ona) |
| HUE067471T2 (hu) | 2018-03-30 | 2024-10-28 | Incyte Corp | Gennyes verejtékmirigy-gyulladás kezelése jak inhibitorok alkalmazásával |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3115496A (en) | 1963-05-13 | 1963-12-24 | Upjohn Co | Certain 3, 4-disubstituted-1, 2, 5-thiadiazole-1, 1-dioxides and their preparation |
| US3115495A (en) | 1963-05-13 | 1963-12-24 | Upjohn Co | Certain 3, 4-diaryl-delta2-1, 2, 5-thiadiazoline-1, 1-dioxides and their preparation |
| BE698156A (cg-RX-API-DMAC7.html) | 1966-05-11 | 1967-10-16 | ||
| DE1669798A1 (de) | 1966-07-28 | 1971-08-26 | Huels Chemische Werke Ag | Verfahren zum Stabilisieren markomolekularer Polyacetale |
| CS214745B2 (en) | 1976-08-28 | 1982-05-28 | Huels Chemische Werke Ag | Shaped and non-shaped products from plastic materials |
| FI76795C (fi) | 1979-09-04 | 1988-12-12 | Bristol Myers Co | Foerfarande foer framstaellning av nya, terapeutiskt anvaendbara 3,4-disubstituerade 1,2,5-tiadiazol-1-oxider och -1,1-dioxider samt nya mellanprodukter. |
| DE3175201D1 (en) | 1980-04-30 | 1986-10-02 | Merck & Co Inc | Aminothiadiazoles as gastric secretion inhibitors |
| US4394508A (en) | 1980-06-07 | 1983-07-19 | Bristol-Myers Company | Chemical compounds |
| US4510309A (en) | 1981-03-03 | 1985-04-09 | Bristol-Myers Company | Histamine H2 -antagonists |
| IE53068B1 (en) | 1981-06-15 | 1988-05-25 | Merck & Co Inc | Diamino isothiazole-1-oxides and -1,1-dioxides as gastic secretion inhibitors |
| GB2124622A (en) | 1982-07-08 | 1984-02-22 | Glaxo Group Ltd | Thiadiazole derivatives |
| FI832519L (fi) * | 1982-07-12 | 1984-01-13 | Bristol Myers Co | Farmaceutiska foerfaranden och sammansaettningar |
| AU2222083A (en) | 1982-12-14 | 1984-06-21 | Smith Kline & French Laboratories Limited | Pyridine derivatives |
| US4863936A (en) | 1982-12-14 | 1989-09-05 | Smith Kline & French Laboratories Limited | 3,5-Substituted-2-pyridyl-alkylaminocyclobutenediones having histamine h1 -antagonist activity |
| JO1279B1 (en) | 1982-12-23 | 1985-04-20 | جون ايف روبرت | Pyridine derivatives |
| DE3309655A1 (de) | 1983-03-17 | 1984-09-20 | Bayer Ag, 5090 Leverkusen | 1,2,5-thiadiazol-1-oxide und 1,1-dioxide, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| US4497810A (en) | 1983-10-14 | 1985-02-05 | Merck & Co., Inc. | Thiatriazine dioxides as gastric anti-secretory agents |
| US4562184A (en) | 1984-04-02 | 1985-12-31 | Merck & Co., Inc. | Substituted-aminohydroxypropoxy-thiadiazoles, β-blocking compositions and use |
| JPS60255756A (ja) | 1984-06-01 | 1985-12-17 | Ikeda Mohandou:Kk | アミノアルキルフエノキシ誘導体 |
| GB8501535D0 (en) | 1985-01-22 | 1985-02-20 | Smith Kline French Lab | Chemical compounds |
| US4978665A (en) | 1987-01-20 | 1990-12-18 | Nissan Chemical Industries Ltd. | 3(2H)pyridazinone, and antagonistic agent against SRS-A containing it |
| JPH02256668A (ja) | 1988-12-20 | 1990-10-17 | Nissan Chem Ind Ltd | ピリダジノン誘導体 |
| US5206252A (en) | 1992-05-08 | 1993-04-27 | American Home Products Corporation | Thiadiazolyl-amino derivatives of benzopyrans and indanes |
| GB9312210D0 (en) | 1993-06-14 | 1993-07-28 | Smithkline Beecham Plc | Chemical compounds |
| US5354763A (en) | 1993-11-17 | 1994-10-11 | American Home Products Corporation | Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones |
| US5506252A (en) | 1993-11-17 | 1996-04-09 | American Home Products Corporation | Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones |
| DE69435133D1 (de) * | 1993-12-10 | 2008-10-09 | Ricoh Kk | Bildextrahierungsverfahren und Gerät, und Bilderkennungsverfahren und Gerät, zum Extrahieren und Erkennen eines bestimmten Bildes aus einem Bildeingabesignal |
| US5550139A (en) | 1994-01-03 | 1996-08-27 | The Wichita State University | Serine protease inhibitors |
| US5466712A (en) | 1994-11-04 | 1995-11-14 | American Home Products Corporation | Substituted n-aryl-1,2-diaminocyclobutene-3,4-diones |
| JPH10509145A (ja) | 1994-11-16 | 1998-09-08 | アメリカン・ホーム・プロダクツ・コーポレイション | ジアミノシクロブテン−３，４−ジオン |
| US5494925A (en) | 1994-12-02 | 1996-02-27 | Sterling Winthrop Inc. | 2-heterocyclyloxymethyl and 2-heterocyclylthiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof |
| US5958957A (en) | 1996-04-19 | 1999-09-28 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
| US5962535A (en) * | 1997-01-17 | 1999-10-05 | Takeda Chemical Industries, Ltd. | Composition for alzheimer's disease |
| IL131004A0 (en) | 1997-01-23 | 2001-01-28 | Smithkline Beecham Corp | Il-8 receptor antagonists |
| US5840764A (en) | 1997-01-30 | 1998-11-24 | American Home Products Corporation | Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones |
| AU6250298A (en) | 1997-01-30 | 1998-08-25 | American Home Products Corporation | Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones |
| AR015425A1 (es) | 1997-09-05 | 2001-05-02 | Smithkline Beecham Corp | Compuestos de benzotiazol, composicion farmaceutica que los contiene, su uso en la manufactura de un medicamento, procedimiento para su preparacion,compuestos intermediarios y procedimiento para su preparacion |
| EP1117633B1 (en) | 1998-10-02 | 2002-09-18 | Neurosearch A/S | Diaminocyclobutene-3,4-dione derivatives, their preparation and use |
| ATE284387T1 (de) | 1998-10-08 | 2004-12-15 | Smithkline Beecham Plc | 3-(3-chloro-4-hydroxyphenylamino)-4-(2- nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3) |
| US6376555B1 (en) | 1998-12-04 | 2002-04-23 | American Home Products Corporation | 4-substituted-3-substituted-amino-cyclobut-3-ene-1,2-diones and analogs thereof as novel potassium channel openers |
| WO2000035855A1 (en) | 1998-12-14 | 2000-06-22 | American Home Products Corporation | 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by vla-4 |
| US6420396B1 (en) | 1998-12-16 | 2002-07-16 | Beiersdorf Ag | Biphenyl and biphenyl-analogous compounds as integrin antagonists |
| NZ512339A (en) | 1998-12-16 | 2003-03-28 | Bayer Ag | New biphenyl and biphenyl-analogous compounds as integrin antagonists |
| US6498161B1 (en) * | 1999-04-06 | 2002-12-24 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
| US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
| CO5190696A1 (es) | 1999-06-16 | 2002-08-29 | Smithkline Beecham Corp | Antagonistas de los receptores il-8 |
| CA2384240A1 (en) * | 1999-10-15 | 2001-04-26 | Dean A. Wacker | Benzylcycloalkyl amines as modulators of chemokine receptor activity |
| US6586446B1 (en) | 1999-10-15 | 2003-07-01 | Bristol-Myers Squibb Company | Bicyclic and tricyclic amines as modulators of chemokine receptor activity |
| AU2001243351A1 (en) | 2000-03-01 | 2001-09-12 | Smith Kline Beecham Corporation | Il-8 receptor antagonists |
| AR033803A1 (es) * | 2000-03-01 | 2004-01-07 | Smithkline Beecham Corp | Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas |
| AU2001245724A1 (en) | 2000-03-14 | 2001-09-24 | Smith Kline Beecham Corporation | Il-8 receptor antagonists |
| HUP0302382A3 (en) | 2000-05-30 | 2004-09-28 | Smithkline Beecham Corp | Il-8 receptor antagonists and pharmaceutical compositions containing them |
| ATE346043T1 (de) | 2001-01-16 | 2006-12-15 | Smithkline Beecham Corp | Il-8-rezeptorantagonisten |
| ATE419845T1 (de) | 2001-01-16 | 2009-01-15 | Smithkline Beecham Corp | Il-8-rezeptor-antagonisten |
| US20030204085A1 (en) | 2001-02-02 | 2003-10-30 | Taveras Arthur G. | 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists |
| CA2436351A1 (en) | 2001-02-02 | 2002-10-03 | Schering Corporation | 3,4-di-substituted cyclobutene-1, 2-diones as cxc chemokine receptor antagonists |
| DK1381590T3 (da) | 2001-04-16 | 2007-10-22 | Schering Corp | 3,4-disubstituerede cyclobuten-1,2-dioner som CXC-kemokinreceptorligander |
| US7132445B2 (en) | 2001-04-16 | 2006-11-07 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| US6903131B2 (en) | 2001-10-12 | 2005-06-07 | Schering Corporation | 3,4-di-substituted maleimide compounds as CXC chemokine receptor antagonists |
| US6878709B2 (en) | 2002-01-04 | 2005-04-12 | Schering Corporation | 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists |
| WO2003080053A1 (en) | 2002-03-18 | 2003-10-02 | Schering Corporation | Combination treatments for chemokine-mediated diseases |
| DE60326080D1 (en) | 2002-10-09 | 2009-03-19 | Schering Corp | Thiadiazoldioxide und thiadiazoloxide als cxc- und cc-chemokinrezeptor liganden |
| TW200530231A (en) | 2003-12-22 | 2005-09-16 | Schering Corp | Isothiazole dioxides as CXC-and CC-chemokine receptor ligands |
| CA2613607A1 (en) * | 2005-06-29 | 2007-01-04 | Schering Corporation | Di-substituted oxadiazoles as cxc-chemokine receptor ligands |
-
2004
- 2004-12-16 AT AT04814266T patent/ATE406356T1/de not_active IP Right Cessation
- 2004-12-16 WO PCT/US2004/042060 patent/WO2005066147A1/en not_active Ceased
- 2004-12-16 DE DE602004016211T patent/DE602004016211D1/de not_active Expired - Lifetime
- 2004-12-16 US US11/013,753 patent/US7338968B2/en not_active Expired - Fee Related
- 2004-12-16 CA CA002550189A patent/CA2550189A1/en not_active Abandoned
- 2004-12-16 CN CN2004800416952A patent/CN1918138B/zh not_active Expired - Fee Related
- 2004-12-16 ES ES04814266T patent/ES2308299T3/es not_active Expired - Lifetime
- 2004-12-16 EP EP04814266A patent/EP1694659B8/en not_active Expired - Lifetime
- 2004-12-16 TW TW093139212A patent/TW200528450A/zh unknown
- 2004-12-16 JP JP2006545364A patent/JP4939229B2/ja not_active Expired - Fee Related
- 2004-12-16 MX MXPA06007076A patent/MXPA06007076A/es active IP Right Grant
- 2004-12-16 MY MYPI20045183A patent/MY139808A/en unknown
- 2004-12-17 AR ARP040104753A patent/AR046791A1/es not_active Application Discontinuation
-
2007
- 2007-09-26 US US11/861,870 patent/US7786149B2/en not_active Expired - Fee Related
-
2011
- 2011-02-15 JP JP2011030301A patent/JP2011093943A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007514746A5 (cg-RX-API-DMAC7.html) | ||
| JP2007515489A5 (cg-RX-API-DMAC7.html) | ||
| CA2550540A1 (en) | Isothiazole dioxides as cxc- and cc- chemokine receptor ligands | |
| AU2020200692B2 (en) | Heterocyclic amides useful as protein modulators | |
| RU2388756C2 (ru) | Кристаллические полиморфные формы лиганда схс-хемокинового рецептора | |
| ES2804707T3 (es) | Compuestos de nicotinamida sustituidos con heteroarilo | |
| CN110099912B (zh) | 抗病毒替诺福韦脂肪族酯前药 | |
| CA2479126A1 (en) | Combination treatments for chemokine-mediated diseases | |
| ES2260415T3 (es) | Triazolopiridinas como agentes antiimflamatorios. | |
| KR102345381B1 (ko) | 키나제 억제제로서 유용한 카르바졸 카르복스아미드 화합물 | |
| ES2783852T3 (es) | Compuestos de aminopiridina sustituidos con heteroarilo | |
| CN108137605B (zh) | Acp-196的晶型及其制备方法和药物组合物 | |
| JP2007537272A5 (cg-RX-API-DMAC7.html) | ||
| BRPI0720196A2 (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica | |
| CA3059939A1 (en) | Indole ahr inhibitors and uses thereof | |
| CN110035760A (zh) | 抗病毒苯甲基胺磷酰二胺化合物 | |
| TW200911232A (en) | Novel therapeutic compounds | |
| US8703788B2 (en) | Polymorph of nilotinib hydrochloride | |
| JP2013518110A5 (cg-RX-API-DMAC7.html) | ||
| HUE029366T2 (en) | Bicyclic-substituted uracil derivatives and their use | |
| TW200813081A (en) | Salts and crystal modifications | |
| CA2575777A1 (en) | Compositions and methods for treatment of colitis using methimazole and/or cyclic thione derivatives | |
| ES2548258T3 (es) | Compuestos de oxadiazol sustituidos y su uso como agonistas de S1P1 | |
| IL279482B2 (en) | Thiophene derivatives for the treatment of disorders caused by ige | |
| JPWO2020033955A5 (cg-RX-API-DMAC7.html) |